{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:46:55Z","timestamp":1791600415888,"version":"4.3.4"},"reference-count":86,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T00:00:00Z","timestamp":1659052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Mpox virus is an emergent human pathogen. While it is less lethal than smallpox, it can still cause significant morbidity and mortality. In this review, we explore 3 antiviral agents with activity against mpox and other orthopoxviruses: cidofovir, brincidofovir, and tecovirimat. Cidofovir, and its prodrug brincidofovir, are inhibitors of DNA replication with a broad spectrum of activity against multiple families of double-stranded DNA viruses. Tecovirimat has more specific activity against orthopoxviruses and inhibits the formation of the extracellular enveloped virus necessary for cell-to-cell transmission. For each agent, we review basic pharmacology, data from animal models, and reported experience in human patients.<\/jats:p>","DOI":"10.1093\/cid\/ciac622","type":"journal-article","created":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T04:49:54Z","timestamp":1659070194000},"page":"155-164","source":"Crossref","is-referenced-by-count":215,"title":["Antivirals With Activity Against Mpox: A Clinically Oriented Review"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4282-4134","authenticated-orcid":false,"given":"Emily A","family":"Siegrist","sequence":"first","affiliation":[{"name":"Department of Pharmacy, OUHealth , Oklahoma City, Oklahoma , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8730-8929","authenticated-orcid":false,"given":"Joseph","family":"Sassine","sequence":"additional","affiliation":[{"name":"Infectious Diseases Section, Department of Medicine, University of Oklahoma Health Sciences Center , Oklahoma City, Oklahoma , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,29]]},"reference":[{"key":"2023010809020016500_ciac622-B1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/oxfordjournals.bmb.a011720","article-title":"Re-emergence of monkeypox in Africa: a review of the past six years","volume":"54","author":"Heymann","year":"1998","journal-title":"Br Med Bull"},{"key":"2023010809020016500_ciac622-B2","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3390\/v12111257","article-title":"Monkeypox virus in Nigeria: infection biology, epidemiology, and evolution","volume":"12","author":"Alakunle","year":"2020","journal-title":"Viruses"},{"key":"2023010809020016500_ciac622-B3","first-page":"1809","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases","author":"Petersen","year":"2020","edition":"9th ed"},{"key":"2023010809020016500_ciac622-B4","first-page":"1818","volume-title":"Mandell, Douglas, and Bennett\u2019s principles and practice of infectious diseases","author":"Petersen","year":"2020","edition":"9th ed"},{"key":"2023010809020016500_ciac622-B5","first-page":"593","article-title":"A human infection caused by monkeypox virus in Basankusu territory, Democratic Republic of the Congo","volume":"46","author":"Ladnyj","year":"1972","journal-title":"Bull World Health Organ"},{"key":"2023010809020016500_ciac622-B6","doi-asserted-by":"crossref","first-page":"e0010141","DOI":"10.1371\/journal.pntd.0010141","article-title":"The changing epidemiology of human monkeypox\u2014a potential threat? A systematic review","volume":"16","author":"Bunge","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"2023010809020016500_ciac622-B7","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1086\/505880","article-title":"Clinical manifestations of human monkeypox influenced by route of infection","volume":"194","author":"Reynolds","year":"2006","journal-title":"J Infect Dis"},{"key":"2023010809020016500_ciac622-B8","first-page":"642","article-title":"Update: multistate outbreak of monkeypox\u2014Illinois, Indiana, Kansas, Missouri, Ohio, and Wisconsin, 2003","volume":"52","author":"Centers for Disease Control and Prevention","year":"2003","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023010809020016500_ciac622-B9","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/cid\/cit703","article-title":"Human monkeypox","volume":"58","author":"McCollum","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2023010809020016500_ciac622-B10","first-page":"465","article-title":"Human monkeypox: secondary attack rates","volume":"66","author":"Jezek","year":"1988","journal-title":"Bull World Health Organ"},{"key":"2023010809020016500_ciac622-B11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1099\/vir.0.005108-0","article-title":"A prairie dog animal model of systemic orthopoxvirus disease using West African and Congo basin strains of monkeypox virus","volume":"90","author":"Hutson","year":"2009","journal-title":"J Gen Virol"},{"key":"2023010809020016500_ciac622-B12","doi-asserted-by":"crossref","first-page":"428","DOI":"10.4269\/ajtmh.2005.73.428","article-title":"Extended interhuman transmission of monkeypox in a hospital community in the Republic of the Congo, 2003","volume":"73","author":"Learned","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"2023010809020016500_ciac622-B13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/ije\/17.3.643","article-title":"The transmission potential of monkeypox virus in human populations","volume":"17","author":"Fine","year":"1988","journal-title":"Int J Epidemiol"},{"key":"2023010809020016500_ciac622-B14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/jmv.25348","article-title":"A review of the monkeypox virus and a recent outbreak of skin rash disease in Nigeria","volume":"91","author":"Kabuga","year":"2019","journal-title":"J Med Virol"},{"key":"2023010809020016500_ciac622-B15","author":"Jezek","year":"1988"},{"key":"2023010809020016500_ciac622-B16","doi-asserted-by":"crossref","first-page":"e0007791","DOI":"10.1371\/journal.pntd.0007791","article-title":"A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy","volume":"13","author":"Beer","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"2023010809020016500_ciac622-B17","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1099\/vir.0.81215-0","article-title":"A tale of two clades: monkeypox viruses","volume":"86","author":"Likos","year":"2005","journal-title":"J Gen Virol"},{"key":"2023010809020016500_ciac622-B18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jcv.2006.03.012","article-title":"Detection of monkeypox virus with real-time PCR assays","volume":"36","author":"Li","year":"2006","journal-title":"J Clin Virol"},{"key":"2023010809020016500_ciac622-B19","first-page":"867","article-title":"Characterization of acute-phase humoral immunity to monkeypox: use of immunoglobulin M enzyme-linked immunosorbent assay for detection of monkeypox infection during the 2003 North American outbreak","volume":"12","author":"Karem","year":"2005","journal-title":"Clin Diagn Lab Immunol"},{"key":"2023010809020016500_ciac622-B20","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S1473-3099(22)00228-6","article-title":"Clinical features and management of human monkeypox: a retrospective observational study in the UK","volume":"22","author":"Adler","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023010809020016500_ciac622-B21","author":"Centers for Disease Control and Prevention"},{"key":"2023010809020016500_ciac622-B22","author":"World Health Organization"},{"key":"2023010809020016500_ciac622-B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0166-3542(02)00008-6","article-title":"Cidofovir in the treatment of poxvirus infections","volume":"55","author":"De Clercq","year":"2002","journal-title":"Antiviral Res"},{"key":"2023010809020016500_ciac622-B24","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1128\/AAC.49.8.3153-3162.2005","article-title":"Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate","volume":"49","author":"Magee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B25","doi-asserted-by":"crossref","first-page":"A84","DOI":"10.1016\/j.antiviral.2009.01.005","article-title":"Alkoxyalkyl prodrugs of acyclic nucleoside phosphonates enhance oral antiviral activity and reduce toxicity: current state of the art","volume":"82","author":"Hostetler","year":"2009","journal-title":"Antiviral Res"},{"key":"2023010809020016500_ciac622-B26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1124\/mol.63.3.678","article-title":"Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14)C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism","volume":"63","author":"Aldern","year":"2003","journal-title":"Mol Pharmacol"},{"key":"2023010809020016500_ciac622-B27","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1128\/JVI.00605-06","article-title":"Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice","volume":"80","author":"Andrei","year":"2006","journal-title":"J Virol"},{"key":"2023010809020016500_ciac622-B28","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1743-422X-7-110","article-title":"Comparative whole genome sequence analysis of wild-type and cidofovir-resistant monkeypoxvirus","volume":"7","author":"Farlow","year":"2010","journal-title":"Virol J"},{"key":"2023010809020016500_ciac622-B29","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1128\/AAC.00380-06","article-title":"Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype","volume":"50","author":"Kornbluth","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B30","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/infdis\/171.4.788","article-title":"(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I\/II study of a novel antiviral nucleotide analogue","volume":"171","author":"Lalezari","year":"1995","journal-title":"J Infect Dis"},{"key":"2023010809020016500_ciac622-B31","first-page":"315","article-title":"Effect of probenecid on the distribution, metabolism, and excretion of cidofovir in rabbits","volume":"24","author":"Cundy","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"2023010809020016500_ciac622-B32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.31646\/gbio.12","article-title":"Efficacy of three key antiviral drugs used to treat orthopoxvirus infections: a systematic review","volume":"1","author":"Yu","year":"2019","journal-title":"Global Biosecurity"},{"key":"2023010809020016500_ciac622-B33","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1128\/AAC.47.10.3275-3280.2003","article-title":"Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice","volume":"47","author":"Quenelle","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B34","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1128\/AAC.48.6.2267-2273.2004","article-title":"Efficacy of cidofovir in a murine model of disseminated progressive vaccinia","volume":"48","author":"Neyts","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2007.11.013","article-title":"Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment","volume":"31","author":"Smee","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2023010809020016500_ciac622-B36","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1128\/JVI.00984-08","article-title":"Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox","volume":"83","author":"Wei","year":"2009","journal-title":"J Virol"},{"key":"2023010809020016500_ciac622-B37","article-title":"Successful cidofovir treatment of smallpox-like disease in variola and monkeypox primate models","author":"Huggins"},{"key":"2023010809020016500_ciac622-B38","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/archderm.1997.03890440061010","article-title":"Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir","volume":"133","author":"Meadows","year":"1997","journal-title":"Arch Dermatol"},{"key":"2023010809020016500_ciac622-B39","first-page":"329","article-title":"Cowpox virus infection in pet rat owners: not always immediately recognized","volume":"106","author":"Becker","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"2023010809020016500_ciac622-B40","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamaophthalmol.2013.264","article-title":"Clinicopathological findings in persistent corneal cowpox infection","volume":"131","author":"Graef","year":"2013","journal-title":"JAMA Ophthalmol"},{"key":"2023010809020016500_ciac622-B41","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1086\/587668","article-title":"Severe eczema vaccinatum in a household contact of a smallpox vaccinee","volume":"46","author":"Vora","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2023010809020016500_ciac622-B42","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/archderm.136.8.983","article-title":"Topical cidofovir: a novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1","volume":"136","author":"Toro","year":"2000","journal-title":"Arch Dermatol"},{"key":"2023010809020016500_ciac622-B43","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/jmv.1084","article-title":"A case of human orf in an immunocompromised patient treated successfully with cidofovir cream","volume":"64","author":"Geerinck","year":"2001","journal-title":"J Med Virol"},{"key":"2023010809020016500_ciac622-B44","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1046\/j.1468-3083.2000.00184.x","article-title":"Topical cidofovir for severe cutaneous human papillomavirus and molluscum contagiosum infections in patients with HIV\/AIDS. A pilot study","volume":"14","author":"Calista","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010809020016500_ciac622-B45","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0140-6736(99)01782-1","article-title":"Topical cidofovir for severe molluscum contagiosum","volume":"353","author":"Davies","year":"1999","journal-title":"Lancet"},{"key":"2023010809020016500_ciac622-B46","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/ijd.15210","article-title":"Recalcitrant molluscum contagiosum successfully treated with intralesional cidofovir in a patient with HIV\/AIDS","volume":"60","author":"Quintana-Castanedo","year":"2021","journal-title":"Int J Dermatol"},{"key":"2023010809020016500_ciac622-B47","author":"Chimerix"},{"key":"2023010809020016500_ciac622-B48","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J Infect Dis"},{"key":"2023010809020016500_ciac622-B49","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B50","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.46.4.991-995.2002","article-title":"Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir","volume":"46","author":"Kern","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B51","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0166-3542(03)00110-4","article-title":"Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney","volume":"59","author":"Ciesla","year":"2003","journal-title":"Antiviral Res"},{"key":"2023010809020016500_ciac622-B53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/FTD.0000000000000353","article-title":"Brincidofovir is not a substrate for the human organic anion transporter 1: a mechanistic explanation for the lack of nephrotoxicity observed in clinical studies","volume":"38","author":"Tippin","year":"2016","journal-title":"Ther Drug Monit"},{"key":"2023010809020016500_ciac622-B54","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","article-title":"Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model","volume":"77","author":"Parker","year":"2008","journal-title":"Antiviral Res"},{"key":"2023010809020016500_ciac622-B55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.antiviral.2015.02.007","article-title":"The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease","volume":"117","author":"Trost","year":"2015","journal-title":"Antiviral Res"},{"key":"2023010809020016500_ciac622-B56","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.antiviral.2017.04.002","article-title":"Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand white rabbits","volume":"143","author":"Grossi","year":"2017","journal-title":"Antiviral Res"},{"key":"2023010809020016500_ciac622-B57","doi-asserted-by":"crossref","first-page":"e00927\u201320","DOI":"10.1128\/mSphere.00927-20","article-title":"Pharmacokinetics and efficacy of a potential smallpox therapeutic, brincidofovir, in a lethal monkeypox virus animal model","volume":"6","author":"Hutson","year":"2021","journal-title":"mSphere"},{"key":"2023010809020016500_ciac622-B58","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.antiviral.2017.01.009","article-title":"Short-term clinical safety profile of brincidofovir: a favorable benefit-risk proposition in the treatment of smallpox","volume":"143","author":"Chittick","year":"2017","journal-title":"Antiviral Res"},{"key":"2023010809020016500_ciac622-B59","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"2023010809020016500_ciac622-B60","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023010809020016500_ciac622-B61","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.bbmt.2016.12.621","article-title":"Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial","volume":"23","author":"Grimley","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023010809020016500_ciac622-B62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2016.08.024","article-title":"Brincidofovir (CMX-001) for refractory and resistant CMV and HSV infections in immunocompromised cancer patients: a single-center experience","volume":"134","author":"El-Haddad","year":"2016","journal-title":"Antiviral Res"},{"key":"2023010809020016500_ciac622-B63","doi-asserted-by":"crossref","first-page":"e12977","DOI":"10.1111\/tid.12977","article-title":"Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients","volume":"20","author":"Lee","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2023010809020016500_ciac622-B64","doi-asserted-by":"crossref","first-page":"13139","DOI":"10.1128\/JVI.79.20.13139-13149.2005","article-title":"An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge","volume":"79","author":"Yang","year":"2005","journal-title":"J Virol"},{"key":"2023010809020016500_ciac622-B65","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1177\/135965350701200802","article-title":"Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox and camelpox viruses in cell monolayers and organotypic raft cultures","volume":"12","author":"Duraffour","year":"2007","journal-title":"Antivir Ther"},{"key":"2023010809020016500_ciac622-B66","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1128\/AAC.00678-09","article-title":"ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation","volume":"53","author":"Berhanu","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B67","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/infdis\/jis510","article-title":"Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001","volume":"206","author":"Lederman","year":"2012","journal-title":"J Infect Dis"},{"key":"2023010809020016500_ciac622-B68","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1128\/AAC.01689-09","article-title":"Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects","volume":"54","author":"Jordan","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B69","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa1705688","article-title":"Oral tecovirimat for the treatment of smallpox","volume":"379","author":"Grosenbach","year":"2018","journal-title":"N Engl J Med"},{"key":"2023010809020016500_ciac622-B70","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1128\/AAC.00021-09","article-title":"Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246","volume":"53","author":"Huggins","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B71","doi-asserted-by":"crossref","first-page":"9176","DOI":"10.1128\/JVI.02173-10","article-title":"Effective antiviral treatment of systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with monkeypox virus","volume":"85","author":"Smith","year":"2011","journal-title":"J Virol"},{"key":"2023010809020016500_ciac622-B72","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/infdis\/jiy326","article-title":"Effects of treatment delay on efficacy of tecovirimat following lethal aerosol monkeypox virus challenge in cynomolgus macaques","volume":"218","author":"Russo","year":"2018","journal-title":"J Infect Dis"},{"key":"2023010809020016500_ciac622-B73","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/AAC.00879-06","article-title":"Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B74","doi-asserted-by":"crossref","first-page":"5564","DOI":"10.1128\/JVI.03426-12","article-title":"Effects of postchallenge administration of ST-246 on dissemination of IHD-J-Luc vaccinia virus in normal mice and in immune-deficient mice reconstituted with T cells","volume":"87","author":"Zaitseva","year":"2013","journal-title":"J Virol"},{"key":"2023010809020016500_ciac622-B75","doi-asserted-by":"crossref","first-page":"6246","DOI":"10.1128\/AAC.00977-13","article-title":"Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (smallpox)","volume":"57","author":"Mucker","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B76","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1128\/AAC.00762-07","article-title":"Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010809020016500_ciac622-B77","doi-asserted-by":"crossref","first-page":"e3990","DOI":"10.1093\/cid\/ciaa1851","article-title":"Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk?","volume":"73","author":"Pettit","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023010809020016500_ciac622-B78","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijantimicag.2015.05.023","article-title":"Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole: a systematic review","volume":"46","author":"Turner","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"2023010809020016500_ciac622-B79","doi-asserted-by":"crossref","first-page":"e23237","DOI":"10.1371\/journal.pone.0023237","article-title":"Comparison of the safety and pharmacokinetics of ST-246(R) after IV infusion or oral administration in mice, rabbits and monkeys","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"key":"2023010809020016500_ciac622-B80","doi-asserted-by":"crossref","first-page":"509","DOI":"10.15585\/mmwr.mm7114a1","article-title":"Monkeypox in a traveler returning from Nigeria\u2014Dallas, Texas, July 2021","volume":"71","author":"Rao","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023010809020016500_ciac622-B81","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s00467-016-3534-y","article-title":"Fatal disseminated cowpox virus infection in an adolescent renal transplant recipient","volume":"32","author":"Gazzani","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2023010809020016500_ciac622-B82","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.3201\/eid2112.150621","article-title":"Severe ocular cowpox in a human, Finland","volume":"21","author":"Kinnunen","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"2023010809020016500_ciac622-B83","doi-asserted-by":"crossref","first-page":"943","DOI":"10.15585\/mmwr.mm6842a2","article-title":"Novel treatment of a vaccinia virus infection from an occupational needlestick\u2014San Diego, California, 2019","volume":"68","author":"Whitehouse","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2023010809020016500_ciac622-B84","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1093\/cid\/ciz286","article-title":"Preemptive tecovirimat use in an active duty service member who presented with acute myeloid leukemia after smallpox vaccination","volume":"69","author":"Lindholm","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023010809020016500_ciac622-B85","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMicm2033620","article-title":"Orbital cowpox","volume":"384","author":"Kiernan","year":"2021","journal-title":"N Engl J Med"},{"key":"2023010809020016500_ciac622-B86","first-page":"1204","article-title":"Human vaccinia infection after contact with a raccoon rabies vaccine bait\u2014Pennsylvania, 2009","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac622\/45473719\/ciac622.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/1\/155\/48533214\/ciac622.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/1\/155\/48533214\/ciac622.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T04:02:47Z","timestamp":1673150567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/1\/155\/6651596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,29]]},"references-count":86,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,7,29]]},"published-print":{"date-parts":[[2023,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac622","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,7,29]]}}}